ライフサイエンスコーパス: RFA

1 RFA (30 W per 30 second duration) was applied at 5g, 10g

2 RFA and 5-W MWA increased postablation tumor growth rate

3 RFA and SBRT groups were similar with respect to number

4 RFA did not reduce mortality or hospitalization for HF d

5 RFA is considered high-risk when the lesion is in close

6 RFA is well tolerated and efficacious in most but not al

7 RFA parameters, including operation duration and ablatio

8 RFA performed during the same procedure after electrophy

9 RFA was associated with a lower hazard for stroke (hazar

10 RFA was performed to ablate the tumor center alone.

11 RFA-SBRT was the preferred strategy, because RFA-RFA and

12 RFA-SBRT yielded 1.558 QALYs and cost $193 288.

13 ween 2002 and 2013, a total of 237 (SR, 109; RFA, 128) patients with BCLC very early-stage HCC were e

14 ed abnormal in-life observations, but 1 of 4 RFA animals (25%) developed fever and dyspnea.

15 time point, after a mean of 2.5 (range, 2-6) RFA procedures.

16 rotein subunits of DNA REPLICATION FACTOR A (RFA) were produced.

17 rin during radiofrequency catheter ablation (RFA) of atrial fibrillation is associated with a lower r

18 fficacy of radiofrequency catheter ablation (RFA) of VT in ARVD/C, with particular focus on newer abl

19 effect of radiofrequency catheter ablation (RFA) on reducing morbidity and mortality among patients

20 or without radiofrequency catheter ablation (RFA).

21 l approaches, e.g. radio frequency ablation (RFA).

22 e studies combining radiofrequency ablation (RFA) and endoscopic mucosal resection into a single endo

23 blational rim after radiofrequency ablation (RFA) and their role in driving the stimulation of distan

24 Resection and radiofrequency ablation (RFA) are treatment options for hepatocellular carcinoma

25 standard irrigated radiofrequency ablation (RFA) during catheter ablation of AF.

26 otherapy (SBRT) and radiofrequency ablation (RFA) for HCC.

27 -touch multibipolar radiofrequency ablation (RFA) for hepatocellular carcinoma (HCC) that met the Mil

28 erapy (SBRT) versus radiofrequency ablation (RFA) for patients with inoperable localized hepatocellul

29 Radiofrequency ablation (RFA) from the epicardial space for ventricular arrhythmi

30 Radiofrequency ablation (RFA) has been shown to be an effective treatment for LGD

31 mpared with hepatic radiofrequency ablation (RFA) in an animal model.

32 ility and safety of radiofrequency ablation (RFA) in Barrett's esophagus are highlighted in this revi

33 during left atrial radiofrequency ablation (RFA) in comparison with uninterrupted oral vitamin K ant

34 ysplasia treated by radiofrequency ablation (RFA) in the randomized controlled Ablation of Intestinal

35 use of endobiliary radiofrequency ablation (RFA) in the treatment of malignant disease of the bile d

36 Percutaneous radiofrequency ablation (RFA) is a minimally invasive technique that destroys can

37 Radiofrequency ablation (RFA) is a potentially curative therapy for hepatocellula

38 Radiofrequency ablation (RFA) is an established treatment for dysplastic Barrett'

39 t force (CF) during radiofrequency ablation (RFA) is an important determinant of endocardial lesion s

40 Radiofrequency ablation (RFA) is commonly used to treat Barrett's esophagus (BE).

41 ground Percutaneous radiofrequency ablation (RFA) is effective in the management of bone tumors.

42 ne- vs. two-session radiofrequency ablation (RFA) of parathyroid hyperplasia for patients with second

43 Radiofrequency ablation (RFA) of ventricular tachycardia (VT) can fail because of

44 cosal resection and radiofrequency ablation (RFA) therapy.

45 avigated multiprobe radiofrequency ablation (RFA) with intraprocedural image fusion for treatment of

46 lung tumor by using radiofrequency ablation (RFA) with local injection of an immunostimulant, OK-432,

47 ry (CA) injury with radiofrequency ablation (RFA) within the coronary venous system as a function of

48 t: liver resection, radiofrequency ablation (RFA), and liver transplantation.

49 Radiofrequency ablation (RFA), with or without endoscopic resection effectively e

50 ety advantages over radiofrequency ablation (RFA).

51 ultiple sessions of radiofrequency ablation (RFA).

52 r biphasic PFA with radiofrequency ablation (RFA).

53 uently treated with radiofrequency ablation (RFA).

54 rcinoma (HCC) after radiofrequency ablation (RFA).

55 1168 (206 asymptomatic) underwent ablation (RFA group).

56 r thermal ablation (radiofrequency ablation [RFA] or microwave ablation).

57 ) patients and in 8 patients with additional RFA without CA narrowing in any patient.

58 eased to 1.79 +/- 0.31 mmol/L at day 1 after RFA and group 2 decreased to 1.89 +/- 0.26 mmol/L at day

59 years after treatment was 70% and 53% after RFA and 74% and 46% after SBRT.

60 ablation was successful in 98.5%, and after RFA, no patients developed malignant arrhythmias or VF o

61 ients treated, 448 (76%) were assessed after RFA.

62 ml to 145.72 +/- 119.27 pg/ml at 1 day after RFA and in group 2 from 2256.64 +/- 1021.72 pg/ml to 138

63 s (interquartile range, 264-1623 days) after RFA and 848 days (interquartile range, 322-2355 days) af

64 nce of esophageal adenocarcinoma (EAC) after RFA, factors associated with the development of EAC, and

65 lational phosphorylated STAT3 24 hours after RFA, which was suppressed with S3I-201 (percentage of po

66 ompared the rate of progression of LGD after RFA with endoscopic surveillance alone in routine clinic

67 ients with ALP < 566 U/L up to a month after RFA (P < 0.05).

68 re measured at a series of time points after RFA.

69 salvage therapy for local progression after RFA.

70 salvage therapy for local progression after RFA.

71 manageable, but continued surveillance after RFA is essential.

72 determination of poor overall survival after RFA.

73 sess technique effectiveness 4-8 weeks after RFA.

74 ed CEIM and remained BE free at 1 year after RFA had a low risk of BE recurrence.

75 nput variables to a Random Forest Algorithm (RFA).

76 Our novel algorithm, Random Field Aligner (RFA), captures the relationships among the short reads g

77 contrast, esophageal injury occurred in all RFA animals (4 of 4, 100%; P=0.005): a mean of 1.5 mucos

78 luated using a resonance frequency analysis (RFA) (implant stability quotient [ISQ] values).

79 through use of resonance frequency analysis (RFA) and damping capacity analysis (DCA).

80 In this retrospective analysis, RFA was performed in 1133 consecutive patients (mean age

81 sham procedure (5-W MWA: 16.3 mm +/- 1.1 and RFA: 16.3 mm +/- 0.9 vs sham: 13.6 mm +/- 1.3, P < .01,

82 e) was increased for 5-W MWA (82% +/- 5) and RFA (79% +/- 5), followed by 20-W MWA (65% +/- 2), compa

83 imilar pattern of inputs is seen for CFA and RFA, with RFA receiving smaller proportion of inputs fro

84 Pathologic studies showed that the Dbait and RFA combination strongly enhances DNA damage and coagula

85 vascular density was greater for 5-W MWA and RFA (P < .01 vs 20-W MWA and sham).

86 Lower-energy MWA and RFA also resulted in increased HSP 70 expression and mac

87 and VEGF elevations were seen in 5-W MWA and RFA compared with 20-W MWA and sham (P < .05).

88 t 7 days, hepatic ablations with 5-W MWA and RFA increased distant tumor size compared with 20-W MWA

89 6.2% and 6.8+/-6.3% (P=0.343) in the PFA and RFA cohorts, respectively.

90 Step 3 compared the effects of PFA and RFA on the esophagus using a mechanical deviation model

91 The effects of endocardial PFA and RFA on the phrenic nerve were also compared (n=10).

92 minimally invasive techniques such as PN and RFA in a variety of tumors.

93 sess the association between progression and RFA.

94 Endoscopic mucosal resection and RFA are the cornerstones in the management of dysplasia

95 We proposed that RWA and RFA are part of a second motor area, the rostral motor a

96 nd rostrally located motor area with RWA and RFA as its constituents.

97 oma (HCC) who are eligible for both SBRT and RFA.

98 s were 48% versus 18% (P < 0.001) for SR and RFA groups, respectively.

99 s were 49% versus 24% (P < 0.001) for SR and RFA groups, respectively.

100 representations, the rostral forelimb area (RFA) and caudal forelimb area (CFA), eliciting identical

101 whiskers, called the rostral forelimb area (RFA) and the rostral whisker area (RWA).

102 Only a rostral forelimb area (RFA) has been definitively described, besides few report

103 forelimb area (CFA), rostral forelimb area (RFA), hindlimb (HL) cortex (based on intracranial micros

104 of rivaroxaban in the setting of left atrial RFA procedures are lacking.

105 ge, 63+/-10 years) who underwent left atrial RFA procedures between February 2012 and May 2013.

106 In patients undergoing left atrial RFA, continuous periprocedural rivaroxaban use seems to

107 SBRT for local progression (SBRT-SBRT), (b) RFA followed by RFA for local progression (RFA-RFA), (c)

108 RFA-SBRT was the preferred strategy, because RFA-RFA and SBRT-RFA were less effective and more costly

109 Based on histology analysis, before RFA, 71% of patients had high-grade dysplasia or esophag

110 Endoscopic mucosal resection before RFA did not provide any benefit.

111 nderwent endoscopic mucosal resection before RFA.

112 Both RFA and SBRT are effective local treatment options for i

113 le, localized HCC who were eligible for both RFA and SBRT to evaluate the cost-effectiveness of the f

114 ia trial, we found BE to recur after CEIM by RFA in almost one third of patients with baseline dyspla

115 progression (SBRT-SBRT), (b) RFA followed by RFA for local progression (RFA-RFA), (c) SBRT followed b

116 progression (RFA-RFA), (c) SBRT followed by RFA for local progression (SBRT-RFA), and (d) RFA follow

117 ib fractures that were apparently induced by RFA and MWA had organ injury or damage related to fractu

118 stability related to the values obtained by RFA and DCA devices, which could create disagreements an

119 Of patients with BE treated by RFA, 56% were in complete remission after 24 months.

120 aching, by damage in voxels encompassing CFA/RFA; hindlimb placement, by damage in HL; and spontaneou

121 Combined RFA plus S3I-201 reduced systemic distant tumor growth a

122 omography-guided radiofrequency ablation (CT-RFA) and laparoscopic RFA (L-RFA) have been used to trea

123 LTP (73.3% vs. 67.9%, p = 0.8897) between CT-RFA and L-RFA.

124 mall HCC abutting the diaphragm, and both CT-RFA and L-RFA are effective techniques.

125 In conclusion, CT-RFA is a relatively easy and economic technique for recu

126 < 0.0001) were significantly lower in the CT-RFA in comparison to that of L-RFA.

127 e HCC nodules and 11-year experience with CT-RFA.

128 FA for local progression (SBRT-RFA), and (d) RFA followed by SBRT for local progression (RFA-SBRT).

129 During RFA, heparin was given intravenously to maintain an acti

130 ational normalized ratio (INR) levels during RFA have not been defined.

131 a therapeutic activated clotting time during RFA was reduced by 50% in patients with an INR>2.0.

132 domly assigned (2:1 ratio) to receive either RFA (entire BE segment ablated circumferentially) or a s

133 rategies for HGD: (1) esophagectomy, (2) EMR-RFA, and (3) endoscopic surveillance.

134 ion followed by radiofrequency ablation (EMR-RFA) for the treatment of Barrett esophagus with high-gr

135 -old patient, compared to esophagectomy, EMR-RFA yields equivalent utility (11.5 vs 11.4 discounted q

136 Dominance of EMR-RFA over esophagectomy persists for all age groups.

137 effectiveness and cost-effectiveness of EMR-RFA versus esophagectomy for HGD remains unclear.

138 may be managed by surgical resection or EMR-RFA.

139 Existing evidence supports EMR-RFA over esophagectomy for the treatment of esophageal H

140 National guidelines suggest that EMR-RFA is effective at eradicating HGD.

141 Epicardial RFA for ventricular arrhythmias is often limited even wh

142 Epicardial RFA was impeded in the majority of cases targeting the l

143 and assessed the effect of failed epicardial RFA on outcome after ablation procedures for ventricular

144 We assessed reasons for epicardial RFA failure relative to the anatomic target area and the

145 5.0; P<0.001) after no or limited epicardial RFA compared with unlimited RFA, and patients with unlim

146 lesion size with limited data on epicardial RFA and CF.

147 RFA, and patients with unlimited epicardial RFA had better recurrence-free survival rates (P<0.001).

148 Six out of 7 patients had failed RFA attempts (including epicardial in 3).

149 388.13 +/- 890.15 pg/ml at 1 day after first RFA and to 137.26 +/- 107.12 pg/ml at 1 day after second

150 ies were collected 12 months after the first RFA; clearance of HGD, dysplasia, and BE were assessed.

151 ovel lattice-tip catheter designed for focal RFA or PFA ablation.

152 he need for continued surveillance following RFA, even after complete eradication of intestinal metap

153 procedure success rates were 90% and 77% for RFA and cryoablation at the ideal site, respectively.

154 vide major inputs to RWA are the same as for RFA, and the nuclei projecting to CWA are same as for CF

155 ved survival (median, 84 days vs 40 days for RFA alone, P = .0004), with approximately half of the an

156 umors >/= 2 cm, there was decreased FFLP for RFA compared with SBRT (HR, 3.35; P = .025).

157 ld be carefully monitored in preparation for RFA of atrial fibrillation.

158 thus, they were not considered suitable for RFA or microwave ablation.

159 o-pay threshold of $100 000 per QALY gained, RFA-SBRT was preferred in 65.8% of simulations.

160 erparathyroidism underwent ultrasound guided RFA of parathyroid hyperplasia.

161 US-guided RFA of parathyroid hyperplasia is a safe and effective m

162 analysis was performed in mice after hepatic RFA or sham procedure; mice were sacrificed 24 hours to

163 ated in the periablational rim after hepatic RFA, of which STAT3 was active in four of seven.

164 ss off-target tumorigenic effects of hepatic RFA.

165 Next, animals were allocated to hepatic RFA or sham treatment with or without STAT3 (signal tran

166 he Cox proportional hazards model identified RFA as an independent predictor for mortality and tumor

167 However, incomplete RFA can induce accelerated invasive growth at the periph

168 periphery to mild hyperthermia and increases RFA antitumor efficacy.

169 ute coronary injury with direct and indirect RFA and phrenic nerve palsy occurrence was proportional

170 Intraductal RFA, via both endoscopic and percutaneous approaches, is

171 In 12 sheep, a 7-F irrigated RFA catheter with CF sensor was introduced via a pericar

172 d 4 animals received 6 clusters of irrigated RFA applications (30 Wx30 seconds, 3.5 mm catheter).

173 evaluated CF characteristics using irrigated RFA on the epicardium in an ovine model.

174 butting the diaphragm, and both CT-RFA and L-RFA are effective techniques.

175 vs. 67.9%, p = 0.8897) between CT-RFA and L-RFA.

176 wer in the CT-RFA in comparison to that of L-RFA.

177 cy ablation (CT-RFA) and laparoscopic RFA (L-RFA) have been used to treat intrahepatic recurrent smal

178 frequency ablation (CT-RFA) and laparoscopic RFA (L-RFA) have been used to treat intrahepatic recurre

179 Conclusion No-touch multibipolar RFA for HCC tumors that meet Milan criteria provides a h

180 eria were treated with no-touch multibipolar RFA, which consisted of activating, in bipolar mode, thr

181 y 2007 through July 2011 from US multicenter RFA Patient Registry.

182 The necrotic RFA lesions involved multiple esophageal tissue layers w

183 1 (550 asymptomatic) did not undergo RFA (no-RFA group) and 1168 (206 asymptomatic) underwent ablatio

184 In the no-RFA group, VF occurred in 1.5% of patients, virtually ex

185 + complications occurred after 11% and 5% of RFA and SBRT treatments, respectively (P = .31).

186 n rate and risk factors for complications of RFA is lacking.

187 y variables associated with complications of RFA.

188 Connections of RFA, CFA, and the caudally located hindlimb area (CHA),

189 were grouped based on the INR on the day of RFA.

190 urther supported by the inhibitory effect of RFA expression on the cell-to-cell movement of Bean dwar

191 New data on the cost-effectiveness of RFA have also been published, suggesting that RFA is cos

192 of case volume on the safety and efficacy of RFA or about the presence or contour of learning curves

193 l centers on safety and efficacy outcomes of RFA.

194 ging data on the effectiveness and safety of RFA, recurrence and progression of disease remain an iss

195 val (LTPFS) were calculated from the time of RFA by using the Kaplan-Meier method.

196 zed case series have now reported the use of RFA in mixed cohorts of human individuals with pancreati

197 10 minutes, simulating the marginal zone of RFA treatment.

198 ure; patients in the sham group were offered RFA treatment 1 year later, and all patients were follow

199 ion was 163 patients treated with MWA and/or RFA for 195 lung neoplasms between February 2004 and Apr

200 etween patients initially treated with SR or RFA (P = 0.415).

201 udy of PV isolation using either the VGLB or RFA (control).

202 sent in 13.5% of patients after percutaneous RFA and MWA of lung neoplasms.

203 ents with 233 CLMs treated with percutaneous RFA between December 2002 and December 2012.

204 for all arms: 0.60-0.64 mm/d; postablation: RFA: 0.91 mm/d +/- 0.11, 5-W MWA: 0.91 mm/d +/- 0.14, P

205 ) RFA followed by RFA for local progression (RFA-RFA), (c) SBRT followed by RFA for local progression

206 RFA followed by SBRT for local progression (RFA-SBRT).

207 same enrollment criteria but did not receive RFA were matched (</=1:20) by hospitals and dates to ser

208 nts in the AIM Dysplasia trial, 119 received RFA and met inclusion criteria.

209 A total of 846 patients with AF who received RFA and 11 324 matched AF controls were included, with a

210 We followed patients who received RFA for BE containing high-grade intraepithelial neoplas

211 e analysis had been made in various regions; RFA and DCA should have been applied in the same implant

212 Therefore, members of the RSL1/RFA family interact with ABA receptors at plasma membran

213 he RING between RING fingers (RBR)-type RSL1/RFA family, are key regulators of ABA receptor stability

214 Group 1's RFA time and hospitalization were shorter and had lower

215 own of native carbon in raw fly ash samples (RFA) and for the formation and destruction of polychlori

216 preferred strategy, because RFA-RFA and SBRT-RFA were less effective and more costly.

217 followed by RFA for local progression (SBRT-RFA), and (d) RFA followed by SBRT for local progression

218 37.26 +/- 107.12 pg/ml at 1 day after second RFA.

219 Three separate RFAs were trained using feature/response data of varying

220 e lesions (n = 40 [72%]), followed by serial RFA every 3 months.

221 /- 0.26 mmol/L at day 1 after second session RFA (P < 0.05).

222 Single-session RFA was more cost-effective and resulted in a shorter ho

223 However, patients with two-session RFA had less hypocalcemia, especially those with high AL

224 rett's esophagus neoplasia, and a simplified RFA algorithm.

225 Since RFA and resection are not options given tumor location,

226 Although epicardial fat limits lesion size, RFA with high CF can produce small myocardial RF lesions

227 bridging therapy of 195 HCCs by stereotactic RFA (SRFA).

228 Sublethal RFA or Dbait treatment alone moderately improved surviva

229 treated with Dbait alone (n = 20), sublethal RFA (n = 21), three different Dbait schemes and subletha

230 three different Dbait schemes and sublethal RFA (n = 52), or a sham treatment (n = 18).

231 Suboptimal RFA accelerates HCC growth and spread by transiently ind

232 dicted the recurrence of IM after successful RFA.

233 Targeted RFA with a newly developed articulating device is both f

234 copic or computed tomography-guided targeted RFA was performed in 26 patients (47 tumors) with painfu

235 We test RFA through extensive simulations and apply it to discov

236 We demonstrate that RFA facilitates accurate recovery of variation in 155 Mb

237 The observation that RFA complex plants dramatically inhibited the transient

238 FA have also been published, suggesting that RFA is cost-effective for both high-grade and low-grade

239 In the RFA group, ablation was successful in 98.5%, and after R

240 % in the surveillance group and 0.77% in the RFA group.

241 n is correct, we selectively inactivated the RFA/grasp area during the performance of skilled forelim

242 Overexpression of the RFA complex in tobacco resulted in decreased T-DNA expre

243 observed during cooling deactivation of the RFA/grasp area, but not the CFA/arm area.

244 of vWF multimers were used for training the RFA.

245 The mechanisms underlying the RFA-induced tumor promotion remain largely unexplored.

246 using a flow-over solid system in which the RFA samples were thermally treated at 300 degrees C unde

247 3230 adenocarcinoma tumors were allocated to RFA or sham treatment with or without a STAT3 inhibitor

248 dioembolization is a possible alternative to RFA in such cases.

249 egmentectomy in solitary HCC not amenable to RFA or resection.

250 table, solitary HCC </= 5 cm not amenable to RFA were included in this multicenter study.

251 we showed that sources of thalamic inputs to RFA and RWA are similar, but they are different from tho

252 Sources of inputs to RFA, caudal forelimb area (CFA), and caudal hindlimb reg

253 cted recovery of function: damage lateral to RFA reduced recovery of reaching, damage medial to HL re

254 icacy of VGLB ablation proved noninferior to RFA for the treatment of paroxysmal AF.

255 ive, at $558 679 per QALY gained relative to RFA-SBRT.

256 nd increased distant tumor growth similar to RFA in an animal tumor model, higher-power, faster heati

257 lication rate and risk factors of bone tumor RFA.

258 nts, 1001 (550 asymptomatic) did not undergo RFA (no-RFA group) and 1168 (206 asymptomatic) underwent

259 or patients with early-stage HCC who undergo RFA.

260 comes of patients with BE who have undergone RFA for neoplasia.

261 Among patients who have undergone RFA with or without endoscopic resection for neoplastic

262 ctive study of patients who either underwent RFA (n = 45) or surveillance endoscopy (n = 125) for LGD

263 he Milan criteria who subsequently underwent RFA from 2002 to 2013.

264 l resection, and the patients then underwent RFA every 3 months until all areas of BE were ablated or

265 r stroke or heart failure (HF) who underwent RFA between 2003 and 2009 was identified using Taiwan's

266 data for outcomes of patients who underwent RFA for BE from July 2007 through July 2011 from US mult

267 148 institutions) for patients who underwent RFA for BE from July 2007 to July 2011.

268 patients in the United Kingdom who underwent RFA for BE-related neoplasia and found that by 12 months

269 lticenter registry of patients who underwent RFA of BE, less than 1% died from EAC.

270 ations in consecutive patients who underwent RFA of primary or metastatic bone tumors from January 20

271 ificantly lower among patients who underwent RFA than those who underwent surveillance (adjusted haza

272 mited epicardial RFA compared with unlimited RFA, and patients with unlimited epicardial RFA had bett

273 We collected data from the US RFA Patient Registry (from 148 institutions) for patient

274 d self-expanding metal stent clearance using RFA have been published.

275 feasible as a bail-out approach to failed VT RFA, particularly those originating from the left ventri

276 n alternative bail-out approach to failed VT RFA.

277 1 of 22 (50%) and 1 of 15 (7%) patients when RFA was performed within 2 and 3 to 5 mm of a CA, respec

278 first-line curative treatments, among which RFA provided the best value for money.

279 minutes) without histological changes while RFA produced paralysis.

280 ic histopathologic esophageal changes, while RFA demonstrated a spectrum of esophageal lesions includ

281 ands in one session or group 2 (n = 28) with RFA of 2 glands in a first session and other 2 glands in

282 ely assigned to either group 1 (n = 28) with RFA of all 4 glands in one session or group 2 (n = 28) w

283 t 7 days (end diameter: 11.8 mm +/- 0.5 with RFA plus S3I-201, 19.8 mm +/- 0.7 with RFA alone, and 15

284 with RFA plus S3I-201, 19.8 mm +/- 0.7 with RFA alone, and 15 mm +/- 0.7 with sham procedure; P < .0

285 effect on stroke prevention associated with RFA was suggested, residual confounding attributable to

286 No deaths were associated with RFA.

287 geal lumen produced mild edema compared with RFA (13 [12-14] applications) which produced epithelial

288 es better long-term OS and RFS compared with RFA in patients with BCLC very early-stage HCC.

289 hageal or phrenic nerve damage compared with RFA.

290 ociated with better OS and RFS compared with RFA; the 5-year OS rates were 80% versus 66% (P = 0.034)

291 Combining Dbait with RFA sensitizes the tumor periphery to mild hyperthermia

292 The risk of CA injury with RFA is correlated inversely with the distance from the a

293 , 3 of whom were successfully reablated with RFA.

294 tern of inputs is seen for CFA and RFA, with RFA receiving smaller proportion of inputs from the fore

295 normal non-tumor-bearing liver treated with RFA (70 degrees C x 5 minutes), rapid higher-power MWA (

296 predicted for FFLP in patients treated with RFA (hazard ratio [HR], 1.54 per cm; P = .006), but not

297 data from 592 patients with BE treated with RFA from 2003 through 2011 at 3 tertiary referral center

298 and EAC were lower among those treated with RFA than among untreated patients.

299 One- and 2-year FFLP for tumors treated with RFA were 83.6% and 80.2% v 97.4% and 83.8% for SBRT.

300 s developed in 6.5% of subjects treated with RFA; strictures were the most common complication.